The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
NexoBrid Nexo Pharmaceuticals Pty Ltd
Product name
NexoBrid
Sponsor
Accepted date
Jul-2024
Active ingredients
anacaulase-bcdb
Proposed indication
For use as a temporary debriding agent/ removal of eschar in burns patients.
Application type
A (new medicine)
Publication date
Jul-2024
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.